CANCER:

Gastroesophageal Cancer

Related cancers:

‹

Gastric Cancer (605)

Gastroesophageal Junction Adenocarcinoma (138)

Gastric Adenocarcinoma (34)

Gastric Cancer (605)

Gastroesophageal Junction Adenocarcinoma (138)

Gastric Adenocarcinoma (34)

›

HER-2 positive HER-2 positive	Gastroesophageal Cancer Gastroesophageal Cancer	HER-2 positive HER-2 positive	Gastroesophageal Cancer Gastroesophageal Cancer	trastuzumab Sensitive: A2 - Guideline	trastuzumab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Gastroesophageal Cancer Gastroesophageal Cancer	PD-L1 overexpression PD-L1 overexpression	Gastroesophageal Cancer Gastroesophageal Cancer	PD1 inhibitor Sensitive: B - Late Trials	PD1 inhibitor Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Gastroesophageal Cancer Gastroesophageal Cancer	PD-L1 overexpression PD-L1 overexpression	Gastroesophageal Cancer Gastroesophageal Cancer	PD-L1 inhibitor Sensitive: B - Late Trials	PD-L1 inhibitor Sensitive: B - Late Trials
HER-2 amplification HER-2 amplification	Gastroesophageal Cancer Gastroesophageal Cancer	HER-2 amplification HER-2 amplification	Gastroesophageal Cancer Gastroesophageal Cancer	trastuzumab Sensitive: B - Late Trials	trastuzumab Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Gastroesophageal Cancer Gastroesophageal Cancer	PD-L1 expression PD-L1 expression	Gastroesophageal Cancer Gastroesophageal Cancer	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
HER-2 positive HER-2 positive	Gastroesophageal Cancer Gastroesophageal Cancer	HER-2 positive HER-2 positive	Gastroesophageal Cancer Gastroesophageal Cancer	pembrolizumab + trastuzumab Sensitive: C1 - Off-label	pembrolizumab + trastuzumab Sensitive: C1 - Off-label
HER-2 positive HER-2 positive	Gastroesophageal Cancer Gastroesophageal Cancer	HER-2 positive HER-2 positive	Gastroesophageal Cancer Gastroesophageal Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria	pembrolizumab Sensitive: C2 – Inclusion Criteria
TP53 mutation TP53 mutation	Gastroesophageal Cancer Gastroesophageal Cancer	TP53 mutation TP53 mutation	Gastroesophageal Cancer Gastroesophageal Cancer	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
TET1 mutation TET1 mutation	Gastroesophageal Cancer Gastroesophageal Cancer	TET1 mutation TET1 mutation	Gastroesophageal Cancer Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
HER-2 expression HER-2 expression	Gastroesophageal Cancer Gastroesophageal Cancer	HER-2 expression HER-2 expression	Gastroesophageal Cancer Gastroesophageal Cancer	ZW25 Sensitive: C3 – Early Trials	ZW25 Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	Gastroesophageal Cancer Gastroesophageal Cancer	PD-L1 expression PD-L1 expression	Gastroesophageal Cancer Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
HER-2 overexpression HER-2 overexpression	Gastroesophageal Cancer Gastroesophageal Cancer	HER-2 overexpression HER-2 overexpression	Gastroesophageal Cancer Gastroesophageal Cancer	disitamab vedotin Sensitive: C3 – Early Trials	disitamab vedotin Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	Gastroesophageal Cancer Gastroesophageal Cancer	PD-L1 expression PD-L1 expression	Gastroesophageal Cancer Gastroesophageal Cancer	tislelizumab Sensitive: C3 – Early Trials	tislelizumab Sensitive: C3 – Early Trials
FGFR2 amplification FGFR2 amplification	Gastroesophageal Cancer Gastroesophageal Cancer	FGFR2 amplification FGFR2 amplification	Gastroesophageal Cancer Gastroesophageal Cancer	ABSK091 Sensitive: C3 – Early Trials	ABSK091 Sensitive: C3 – Early Trials
MET amplification MET amplification	Gastroesophageal Cancer Gastroesophageal Cancer	MET amplification MET amplification	Gastroesophageal Cancer Gastroesophageal Cancer	crizotinib Sensitive: C3 – Early Trials	crizotinib Sensitive: C3 – Early Trials
TGFB1 elevation TGFB1 elevation	Gastroesophageal Cancer Gastroesophageal Cancer	TGFB1 elevation TGFB1 elevation	Gastroesophageal Cancer Gastroesophageal Cancer	M7824 Sensitive: C3 – Early Trials	M7824 Sensitive: C3 – Early Trials
HER-2 overexpression HER-2 overexpression	Gastroesophageal Cancer Gastroesophageal Cancer	HER-2 overexpression HER-2 overexpression	Gastroesophageal Cancer Gastroesophageal Cancer	ZW25 Sensitive: C3 – Early Trials	ZW25 Sensitive: C3 – Early Trials
MET amplification MET amplification	Gastroesophageal Cancer Gastroesophageal Cancer	MET amplification MET amplification	Gastroesophageal Cancer Gastroesophageal Cancer	afatinib Resistant: C3 – Early Trials	afatinib Resistant: C3 – Early Trials
EGFR amplification + ERBB2 amplification EGFR amplification + ERBB2 amplification	Gastroesophageal Cancer Gastroesophageal Cancer	EGFR amplification + ERBB2 amplification EGFR amplification + ERBB2 amplification	Gastroesophageal Cancer Gastroesophageal Cancer	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
CFB overexpression CFB overexpression	Gastroesophageal Cancer Gastroesophageal Cancer	CFB overexpression CFB overexpression	Gastroesophageal Cancer Gastroesophageal Cancer	sunitinib Sensitive: C3 – Early Trials	sunitinib Sensitive: C3 – Early Trials
VEGFC-H VEGFC-H	Gastroesophageal Cancer Gastroesophageal Cancer	VEGFC-H VEGFC-H	Gastroesophageal Cancer Gastroesophageal Cancer	sunitinib Sensitive: C3 – Early Trials	sunitinib Sensitive: C3 – Early Trials
HER-2 positive HER-2 positive	Gastroesophageal Cancer Gastroesophageal Cancer	HER-2 positive HER-2 positive	Gastroesophageal Cancer Gastroesophageal Cancer	pembrolizumab + margetuximab Sensitive: C3 – Early Trials	pembrolizumab + margetuximab Sensitive: C3 – Early Trials
POLE mutation POLE mutation	Gastroesophageal Cancer Gastroesophageal Cancer	POLE mutation POLE mutation	Gastroesophageal Cancer Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
POLD1 mutation POLD1 mutation	Gastroesophageal Cancer Gastroesophageal Cancer	POLD1 mutation POLD1 mutation	Gastroesophageal Cancer Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	Gastroesophageal Cancer Gastroesophageal Cancer	PD-L1 expression PD-L1 expression	Gastroesophageal Cancer Gastroesophageal Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	Gastroesophageal Cancer Gastroesophageal Cancer	PD-L1 expression PD-L1 expression	Gastroesophageal Cancer Gastroesophageal Cancer	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
HER-2 positive + HER-2 amplification HER-2 positive + HER-2 amplification	Gastroesophageal Cancer Gastroesophageal Cancer	HER-2 positive + HER-2 amplification HER-2 positive + HER-2 amplification	Gastroesophageal Cancer Gastroesophageal Cancer	trastuzumab Sensitive: C3 – Early Trials	trastuzumab Sensitive: C3 – Early Trials
CTAG1A expression CTAG1A expression	Gastroesophageal Cancer Gastroesophageal Cancer	CTAG1A expression CTAG1A expression	Gastroesophageal Cancer Gastroesophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
HER-2 positive + PD-L1 expression HER-2 positive + PD-L1 expression	Gastroesophageal Cancer Gastroesophageal Cancer	HER-2 positive + PD-L1 expression HER-2 positive + PD-L1 expression	Gastroesophageal Cancer Gastroesophageal Cancer	margetuximab + retifanlimab Sensitive: C3 – Early Trials	margetuximab + retifanlimab Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Gastroesophageal Cancer Gastroesophageal Cancer	HER-2 mutation HER-2 mutation	Gastroesophageal Cancer Gastroesophageal Cancer	dasatinib Sensitive: D – Preclinical	dasatinib Sensitive: D – Preclinical
HER-2 mutation HER-2 mutation	Gastroesophageal Cancer Gastroesophageal Cancer	HER-2 mutation HER-2 mutation	Gastroesophageal Cancer Gastroesophageal Cancer	neratinib Sensitive: D – Preclinical	neratinib Sensitive: D – Preclinical
HER-2 mutation HER-2 mutation	Gastroesophageal Cancer Gastroesophageal Cancer	HER-2 mutation HER-2 mutation	Gastroesophageal Cancer Gastroesophageal Cancer	dasatinib + neratinib Sensitive: D – Preclinical	dasatinib + neratinib Sensitive: D – Preclinical
BCL2 overexpression + MCL1 overexpression BCL2 overexpression + MCL1 overexpression	Gastroesophageal Cancer Gastroesophageal Cancer	BCL2 overexpression + MCL1 overexpression BCL2 overexpression + MCL1 overexpression	Gastroesophageal Cancer Gastroesophageal Cancer	AT 101 Sensitive: D – Preclinical	AT 101 Sensitive: D – Preclinical
ERBB2 G778A + CCNE1 amplification ERBB2 G778A + CCNE1 amplification	Gastroesophageal Cancer Gastroesophageal Cancer	ERBB2 G778A + CCNE1 amplification ERBB2 G778A + CCNE1 amplification	Gastroesophageal Cancer Gastroesophageal Cancer	AZD1775 + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical	AZD1775 + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
HER2 underexpression + CCNE1 amplification HER2 underexpression + CCNE1 amplification	Gastroesophageal Cancer Gastroesophageal Cancer	HER2 underexpression + CCNE1 amplification HER2 underexpression + CCNE1 amplification	Gastroesophageal Cancer Gastroesophageal Cancer	AZD1775 + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical	AZD1775 + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
HER2 amplification + CCNE1 expression HER2 amplification + CCNE1 expression	Gastroesophageal Cancer Gastroesophageal Cancer	HER2 amplification + CCNE1 expression HER2 amplification + CCNE1 expression	Gastroesophageal Cancer Gastroesophageal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical	fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
HER2 overexpression + CCNE1 amplification HER2 overexpression + CCNE1 amplification	Gastroesophageal Cancer Gastroesophageal Cancer	HER2 overexpression + CCNE1 amplification HER2 overexpression + CCNE1 amplification	Gastroesophageal Cancer Gastroesophageal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical	fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
MET amplification MET amplification	Gastroesophageal Cancer Gastroesophageal Cancer	MET amplification MET amplification	Gastroesophageal Cancer Gastroesophageal Cancer	savolitinib + capmatinib Sensitive: D – Preclinical	savolitinib + capmatinib Sensitive: D – Preclinical

Gastroesophageal Cancer

Associations(38)

Associations
(38)